InnoCare's soficitinib hits both co-primary endpoints in Phase 3 atopic dermatitis trial
The oral TYK2 inhibitor cleared vIGA-AD and EASI-75 goals with no new safety signals, but InnoCare has not yet released the effect sizes that would size the win against approved JAK1 rivals.
Executive Summary
- InnoCare's registrational Phase 3 trial of its oral TYK2 inhibitor in moderate-to-severe atopic dermatitis met both co-primary efficacy endpoints, with a safety profile the company says matches earlier studies.
- The company has not released the numeric effect sizes, confidence intervals, or placebo-adjusted response rates behind the topline claim, leaving the size of the benefit to be established when fuller data are presented.
- The win lands in a JAK1/TYK2 inhibitor field that already includes multiple approved oral competitors in atopic dermatitis, so replication of the established efficacy band matters more than the statistical significance alone.
- InnoCare says it will complete the Phase 3 study and advance a regulatory filing, though the specific filing timeline and jurisdiction have not been detailed.
The readout
InnoCare Pharma announced on July 15, 2026 that its Phase 3 trial of soficitinib, a TYK2 inhibitor also classified in the trial registry as a JAK1 inhibitor, met the co-primary endpoints of vIGA-AD 0/1 (clear or almost-clear skin) and EASI-75 (at least a 75% reduction in eczema severity) at Week 16, both with statistical significance. The randomized, double-blind, placebo-controlled trial enrolled 552 adults with moderate-to-severe atopic dermatitis at sites in China, matching its target enrollment exactly. Jasmine Cui, InnoCare's co-founder, chairwoman and CEO, said the company is "happy to see that soficitinib has met the primary endpoint in the Phase III studies in atopic dermatitis with excellent clinical results". InnoCare+1InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint ...Jul 15, 2026ICP-332 in Subjects With Moderate to Severe Atopic DermatitisNCT06775860
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the endpoints measure
vIGA-AD 0/1 requires a two-grade or greater reduction in an investigator-scored global severity rating, while EASI-75 requires a 75% drop in a composite score of lesion area and severity; together they are the standard registrational bar for atopic dermatitis drugs. InnoCare said multiple secondary endpoints were also met, describing a consistent treatment effect across efficacy measures, and reported a safety profile consistent with prior soficitinib studies with no new signals identified. The company has not yet disclosed the numeric response rates, placebo-adjusted treatment differences, or p-values behind either endpoint; it says detailed efficacy and safety data will follow at a scientific congress or in a journal publication. InnoCareInnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint ...Jul 15, 2026
The competitive bar
Oral JAK1 inhibitors are already commercial in atopic dermatitis: Pfizer's abrocitinib and AbbVie's upadacitinib both hold Phase 3 programs in the same indication, and both are approved therapies competing on the same vIGA-AD and EASI-75 endpoints. Because the mechanism class is already validated in this disease, the informative bar for soficitinib is not whether it beat placebo, but whether its effect size approaches the response rates those approved entrants established. Across JAK1-inhibitor Phase 3 trials in atopic dermatitis, 26 of 29 trials completed without termination, a 10% failure rate that favors trials reaching a clean readout.
Sponsor and pipeline context
InnoCare describes soficitinib as a component of a broader dermatology pipeline that also includes development in vitiligo, psoriasis, nodular prurigo and chronic spontaneous urticaria. The sponsor runs 62 trials across its pipeline, with 23 currently recruiting and 13 completed. The trial's registry record shows a single eligibility-criteria amendment since its first posting in January 2025 and no changes to its primary completion date, a stable protocol history for a study that enrolled to its full anticipated target of 552 patients. InnoCare+1InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint ...Jul 15, 2026ICP-332 in Subjects With Moderate to Severe Atopic DermatitisNCT06775860
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.